Developing a molecular “fingerprint” as a non-invasive screen for breast cancer
This translational grant proposes to build on exciting BCRT-funded science that has led to the identification of two RNA markers in the blood, which together may be able to indicate whether a woman has breast cancer or not. We now want to study additional markers to see if, using a combination of markers, we can make our test more accurate and ready for larger scale trials. We will further refine our methods to detect these markers in the blood, and then we will measure them in increasing numbers of breast cancer patients, compared to blood samples from healthy women. We will also assess these markers before and after surgical removal of breast tumours. By combining these markers with the patient’s clinical data, we hope to define a simple blood test that can be used in screening for breast cancer or to indicate whether a breast cancer patient has relapsed.
Keep reading
View all
From Evidence to Action: Expanding the ‘Not a One-Size-Fits-All’ Breast Cancer Screening Model for Aotearoa New Zealand.
Problem:Breast cancer screening in Aotearoa New Zealand does not benefit all women equally. Many cancers are still found outside the national screening programme, and Māori and Pacific women can fa...
Using Deep Learning And Digital Pathology To Intrinsically Subtype Breast Cancer
Problem:Traditional pathology uses microscopes to examine tissue slides, but this method can be slow and inconsistent, and not all patients can afford advanced molecular testing. Project:Digital pa...
“Shielding” Macrophages: Uncovering Immune-Mediated Chemoresistance in Triple-Negative Breast Cancer
ProblemTriple-negative breast cancer (TNBC) is one of the hardest types to treat and affects Māori and Pacific women more than others. Many patients with TNBC don’t fully respond to chemotherapy, a...
